Methods of treating inflammatory and autoimmune diseases with natalizumab

a technology of natalizumab and inflammatory diseases, applied in the field of recombinant antibody treatment of inflammatory and autoimmune diseases, can solve the problems of accumulation of permanent physical disability and cognitive decline, current treatment is minimally effective for secondary progressive ms, and neutralizing antibodies to interferon
US20070207141A1Inactive Publication Date: 2007-09-06BIOGEN MA INC
22 Cites 95 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
BIOGEN MA INC
Publication Date
2007-09-06
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
Need to check novelty before this filing date? Find Prior Art

Description

PRIORITY CLAIM

[0001] This application claims priority to U.S. Provisional Patent Application No. 60 / 776,931,. filed Feb. 28, 2006, which is hereby incorporated herein for all purposes.TECHNICAL FIELD

[0002] The invention relates to methods of treating inflammatory and autoimmune diseases with a recombinant antibody. These methods improve the safety of treatment by informing and monitoring patients undergoing antibody treatment. BACKGROUND ART

[0003] The migration of lymphocytes from the peripheral blood across the blood brain barrier has been reported to initiate the development of several central nervous system (CNS) inflammatory diseases. Lymphocyte entry into the CNS is mediated by cellular adhesion molecules (O'Neill et al., Immunology 72:520-525 (1991); Raine et al., Lab. Invest. 63:476-489 (1990); Yednock et al., Nature 356:63-66 (1992); Baron et al., J. Exp. Med. 177:57-68 (1993); Steffen et al., Am. J. Path 145:189-201 (1994); Christensen et al., J. Immunol. 154:5293-5301 (...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More